Bluebird bio (BLUE), Carlyle (CG), SK Capital Partners and Beacon Parent said late Monday that all required regulatory approvals have been received for the Bluebird bio's acquisition by Carlyle and SK Capital.
The companies said no additional approvals are needed, and the merger is expected to close soon on May 12.
Under the deal, Bluebird bio's shareholders will receive $3 per share in cash upfront and a contingent value right worth up to $6.84 per share, based on future sales milestones, bringing the total potential value to $9.84 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.